For lymphoma patients out of options, Citius Oncology stakes its future on a CD19xCD3 bispecific—and a $37M debt gamble

Inside Citius Oncology’s labs, the mission crystallized around a single patient: a 62-year-old grandmother with diffuse large B-cell lymphoma who had exhausted three lines of therapy. Her T cells, exhausted and outnumbered, were failing to recognize the CD19 proteins swarming on malignant B cells. The company’s answer—a bispecific antibody called CI-102—was designed to grab hold of CD19 with one arm and latch onto the CD3 receptor on those weary T cells with the other, physically bridging the gap and forcing a lethal synapse. In early dose-escalation studies, that forced embrace yielded complete responses in patients who had been measured in weeks, not months. On May 6, 2026, that vision got a $37 million lifeline. Avenue Capital Group led the debt financing, structuring the deal to carry Citius through a pivotal Phase II expansion without the immediate dilution equity markets would demand. The terms signal a calculated bet: CI-102 has already shown it can shrink tumors in heavily pretreated populations, and the fresh funds will accelerate enrollment at major cancer centers, generating the kind of data that could support an accelerated approval pathway. The financing lands amid a broader recalibration in oncology, where debt is rapidly replacing venture equity for mid-stage immuno-oncology assets. With interest rates stabilizing and public investors still nursing wounds from the post-2023 biotech correction, specialized lenders like Avenue have stepped into the void, backing programs with clear biological rationale and clinical proof points rather than broad platform stories. In the hematologic cancer arena, that trend is particularly pronounced as established targets like CD19 and BCMA spawn crowded fields of CAR-T therapies and bispecifics. Citius is betting that CI-102’s subcutaneous formulation and relatively mild cytokine release profile will differentiate it from infused competitors, making it suitable for community oncology settings where most patients receive care. The deal avoids the dreaded ‘capital infusion’ label, framing the debt as working capital to bridge manufacturing scale-up and biomarker studies that could identify patients most likely to achieve durable remissions. As the grandmother’s scans showed no evidence of disease at six months, the company sees a path where a single antibody could rewrite the odds for the thousands who relapse each year.